Maravai LifeSciences - Class A opened higher at $7.93, compared with its previous close of $7.70. In the last trading session, the stock traded between $7.60 and $7.93. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Maravai LifeSciences - Class A is now worth
$ 21.10
Resulting in a loss of
$ 78.90 (78.90%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.01 (-0.18%)
Day High
$7.93
Day Low
$7.60
Day Open
$7.93
Prev Close
$7.70
Volume
21,03,072
1W Return
-0.59%
1M Return
8.77%
3M Return
32.20%
6M Return
62.15%
1Y Return
136.49%
Fundamentals
Market Cap ($ Mn)
1,147
PE Ratio
-
PB Ratio
5.59
PEG Ratio
-
ROE
-85.49%
ROCE
-26.19%
EPS (TTM)
$-0.09
Investment Returns
1 Week
-0.59%
1 Month
8.77%
3 Months
32.20%
6 Months
62.15%
9 Months
146.35%
Financials
Quarterly
All values in $ Mn
47.4
Jun 25
41.6
Sep 25
49.9
Dec 25
65.8
Mar 26
51.4
Jun 26
45.9
Sep 26
Updates
12Nov
KeyBanc upgrades Maravai LifeSciences to Overweight with $11 target
KeyBanc upgraded Maravai LifeSciences from Sector Weight to Overweight. Analyst Paul Knight set a new price target of $11. The move signals improved confidence in the stock's near-term performance.
Today
5Nov
Maravai LifeSciences Q3FY26 Results: Revenue up 10% YoY, guidance raised
Revenue rose 10% YoY to $45.9 million, led by 28% growth in mRNA products. Adjusted EBITDA improved by $16.6 million YoY to $5.8 million. Full-year FY26 revenue guidance raised to $212-$216 million. Adjusted gross margin expanded over 1,700 bps to 57.7%.
8 days ago
15Oct
Maravai LifeSciences sets Nov 4 date for Q3 earnings release
Earnings release scheduled for November 4, 2026. Conference call set for 5:00 pm ET same day. Results cover third quarter financial and operating data.
29 days ago
13Oct
Maravai LifeSciences Q2 revenue up 9% to $51.4m; EBITDA hits $8.7m
Revenue grew 9% YoY to $51.4 million, driven by 12% growth in TriLink. Adjusted EBITDA improved by $19.1 million YoY to $8.7 million. Adjusted gross margin expanded over 1,600 bps to 58.9%. Full-year adjusted EBITDA guidance raised to $33-$35 million. Debt reduced to ~$150 million with maturities extended to 2032.
1mo ago
30Sep
TriLink secures China patent for CleanCap mRNA technology
TriLink BioTechnologies secured a new CNIPA patent (ZL202511246658.5) for CleanCap technology. New patent protects cap analog compounds and pharmaceutical compositions, unlike previous method-only patent. Portfolio now spans US, EU, Australia, Japan, Korea, Hong Kong, Canada, and China. CleanCap is used in approved COVID-19 vaccines and various mRNA therapeutic programs.
1mo ago
23Jul
Maravai LifeSciences to announce Q2 results on August 6
Maravai LifeSciences, Inc. will announce its second quarter financial and operating results for the period ending June 30, 2026, after the market close on August 6, 2026. The company will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss the performance.
